Nelson L. Michael
A5036265394- HIV Research and Treatment
- HIV/AIDS Research and Interventions
- Immune Cell Function and Interaction
- HIV/AIDS drug development and treatment
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- SARS-CoV-2 and COVID-19 Research
- Immunotherapy and Immune Responses
- Hepatitis C virus research
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis B Virus Studies
- Virology and Viral Diseases
- Mosquito-borne diseases and control
- HIV-related health complications and treatments
- Adolescent Sexual and Reproductive Health
- Herpesvirus Infections and Treatments
- HIV, Drug Use, Sexual Risk
- Viral Infections and Vectors
- Cytomegalovirus and herpesvirus research
- Sex work and related issues
- COVID-19 Clinical Research Studies
- Viral Infections and Outbreaks Research
- Animal Virus Infections Studies
- Malaria Research and Control
- SARS-CoV-2 detection and testing
Walter Reed Army Institute of Research
2016-2025
Makerere University Walter Reed Project
2010-2024
University of Maryland, Baltimore
1998-2023
Henry M. Jackson Foundation
2010-2023
National Center for Infectious Diseases
2021-2022
Johns Hopkins University
2015-2021
Jackson Foundation
1996-2021
Fred Hutch Cancer Center
2021
Armed Forces Research Institute of Medical Science
2010-2020
Royal Thai Army
2020
The development of a safe and effective vaccine against the human immunodeficiency virus type 1 (HIV-1) is critical to pandemic control.In community-based, randomized, multicenter, double-blind, placebo-controlled efficacy trial, we evaluated four priming injections recombinant canarypox vector (ALVAC-HIV [vCP1521]) plus two booster glycoprotein 120 subunit (AIDSVAX B/E). placebo were administered 16,402 healthy men women between ages 18 30 years in Rayong Chon Buri provinces Thailand....
In the RV144 trial, estimated efficacy of a vaccine regimen against human immunodeficiency virus type 1 (HIV-1) was 31.2%. We performed case–control analysis to identify antibody and cellular immune correlates infection risk.
Background. Understanding the earliest central nervous system (CNS) events during human immunodeficiency virus (HIV) infection is crucial to knowledge of neuropathogenesis, but these have not previously been described in humans.
Zika virus (ZIKV) is responsible for a major ongoing epidemic in the Americas and has been causally associated with fetal microcephaly. The development of safe effective ZIKV vaccine therefore an urgent global health priority. Here we demonstrate that three different platforms protect against challenge rhesus monkeys. A purified inactivated induced ZIKV-specific neutralizing antibodies completely protected monkeys strains from both Brazil Puerto Rico. Purified immunoglobulin vaccinated also...
A V1-V2 IgG3 response to HIV correlates with a decreased risk of HIV-1 infection and is one vaccine-induced humoral that higher in clinical trial showing vaccine efficacy compared nonefficacy.
SARS-CoV-2 and Immunosuppression In this article, the authors discuss challenges of infection in patients with a weakened immune system, including potential implications regardin...
Analysis of correlates risk infection in the RV144 HIV-1 vaccine efficacy trial demonstrated that plasma IgG against envelope (Env) variable region 1 and 2 inversely correlated with risk, whereas Env-specific IgA responses directly risk. In secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was another inverse correlate but only presence low antibodies. Thus, we investigated hypothesis could attenuate protective effect through competition for same Env binding sites. We...
The human phase 2B RV144 ALVAC-HIV vCP1521/AIDSVAX B/E vaccine trial, held in Thailand, resulted an estimated 31.2% efficacy against HIV infection. By contrast, vaccination with VAX003 (consisting of only AIDSVAX B/E) was not protective. Because protection within observed the absence neutralizing antibody activity or cytotoxic T cell responses, we speculated that specificity qualitative differences Fc-effector profiles nonneutralizing antibodies may have accounted for between two trials. We...
A variant upstream of human leukocyte antigen C (HLA-C) shows the most significant genome-wide effect on HIV control in European Americans and is also associated with level HLA-C expression. We characterized differential cell surface expression levels all common allotypes tested directly for effects outcomes infection 5243 individuals. Increasing was protection against multiple independently individual HLA allelic both African Americans, regardless their distinct frequencies linkage...
The worst Ebola virus disease (EVD) outbreak in history has resulted more than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials an attenuated, replication-competent, recombinant vesicular stomatitis (rVSV)-based vaccine candidate designed to prevent EVD.
The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. secondary immune correlate analysis demonstrated that the combination low plasma anti-HIV-1 Env IgA antibodies and high levels antibody-dependent cellular cytotoxicity (ADCC) inversely with infection risk. One hypothesis is observed protection in partially due to ADCC-mediating antibodies. We found majority (73 90%) a representative group vaccinees displayed ADCC activity, usually (96.2%) blocked by...
Background Limited knowledge exists on early HIV events that may inform preventive and therapeutic strategies. This study aims to characterize the earliest immunologic virologic following infection investigates usage of a novel strategy. Methods Findings We prospectively screened 24,430 subjects in Bangkok identified 40 AHI individuals. Thirty Thais were enrolled (8 Fiebig I, 5 II, 15 III, 2 IV) whom completed 24 weeks megaHAART (tenofovir/emtricitabine/efavirenz/raltegravir/maraviroc)....
A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in community-based population Thailand (RV144 trial). No was observed Thai injection drug users who received AIDSVAX B/E alone (Vax003 We compared the neutralizing antibody response these 2 trials.